Pharmaceutical Intermediate Setipiprant 99% API Powder Setipiprant

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: SASE-Setipiprant
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Powder
• Purity: >99%
• Product Name: Setipiprant
• Name: Setipiprant Powder
• Appearance: White Powder
• Color: White
• Grade: Pharmaceutical Grade
• Assay: 99%
• Specific: COA
• Test Method: HPLC
• CAS: 866460-33-5
• Mf: C24h19fn2o3
• Refractive Index: 1.682
• MW: 402.42
• Density: 1.37
• Boiling Point: 690.4
• Shelf Life: 2 Years
• Transport Package: Negotiable
• Specification: Negotiable
• Trademark: SASE
• Origin: Shaanxi Xi'an
• Production Capacity: 500kg/Month

Product Description

Pharmaceutical Intermediate Setipiprant 99% API Powder Setipiprant

Product Description

Product Details

Product Name	Setipiprant
Appearance	White Powder
CAS No.	866460-33-5
MF	C24h19fn2o3
MW	402.42

Setipiprant is a selective CRTH2 receptor antagonist designed to inhibit prostaglandin D2 (PGD2)-mediated inflammatory responses. By blocking the interaction between PGD2 and CRTH2 receptors, it effectively mitigates allergic inflammation and immune activation, showing potential in treating conditions like androgenetic alopecia (hair loss) and allergic asthma. Its targeted mechanism helps reduce hair follicle miniaturization while promoting scalp health, and may also alleviate airway inflammation. Recognized for its high specificity and favorable safety profile, Setipiprant is emerging as a promising candidate in dermatological and respiratory disease research.

Application&Function

Setipiprant is a highly selective CRTH2 receptor antagonist that exerts its therapeutic effects by specifically blocking the binding pathway of prostaglandin D2 (PGD2) to CRTH2 receptors, thereby effectively modulating various inflammatory responses and immune processes. This compound demonstrates unique advantages in treating androgenetic alopecia, where it potently inhibits PGD2-induced hair follicle miniaturization, improves the perifollicular microenvironment, and promotes the restoration of healthy hair growth cycles. In allergic respiratory diseases such as asthma, Setipiprant exhibits remarkable intervention efficacy by reducing eosinophil infiltration and suppressing Th2-type immune responses, which alleviates airway hyperresponsiveness and inflammatory damage. Emerging research also suggests its potential benefits in atopic dermatitis and other allergic conditions through modulation of mast cell activation and cytokine release. With its carefully optimized molecular structure, Setipiprant maintains exceptional receptor selectivity while demonstrating favorable tissue distribution characteristics and metabolic stability, making it an ideal candidate for the long-term management of chronic inflammatory disorders. The compound's multi-faceted pharmacological profile continues to attract significant interest in both dermatological and respiratory therapeutic areas.

Specification